ResearcherAzienda Ospedaliero-Universitaria CareggiNo recent work listed
Domenico Prisco
Matched on ORCID iD 0000-0002-7787-9610; OpenAlex author ID A5019243176. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 1, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 6
2013: 2 papers · 2014: 1 paper · 2015: none · 2016: 2 papers
Papers 5
- Intra-tumoral IFN-γ-producing Th22 cells correlate with TNM staging and the worst outcomes in pancreatic cancer. Co-author DOI 10.1042/cs20150437↗
- Peripheral ENO1-specific T cells mirror the intratumoral immune response and their presence is a potential prognostic factor for pancreatic adenocarcinoma. Co-author DOI 10.3892/ijo.2016.3524↗
- Pancreatic cancer: role of the immune system in cancer progression and vaccine-based immunotherapy. Last author DOI 10.4161/hv.34392↗
- Ex vivo analysis of pancreatic cancer-infiltrating T lymphocytes reveals that ENO-specific Tregs accumulate in tumor tissue and inhibit Th1/Th17 effector cell … Co-author DOI 10.1007/s00262-013-1429-3↗
- What is recent in pancreatic cancer immunotherapy? First author DOI 10.1155/2013/492372↗
Closest collaborators
The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Amedeo Amedei · 5 shared papers, 2013–2016 · strength 0.25
- Paper Pancreatic cancer: role of the immune system in cancer progression and vaccine-based immunotherapy. DOI 10.4161/hv.34392↗
- Paper What is recent in pancreatic cancer immunotherapy? DOI 10.1155/2013/492372↗
- Paper Peripheral ENO1-specific T cells mirror the intratumoral immune response and their presence is a potential prognostic f… DOI 10.3892/ijo.2016.3524↗
- Elena Niccolai · 5 shared papers, 2013–2016 · strength 0.25
- Paper Pancreatic cancer: role of the immune system in cancer progression and vaccine-based immunotherapy. DOI 10.4161/hv.34392↗
- Paper What is recent in pancreatic cancer immunotherapy? DOI 10.1155/2013/492372↗
- Paper Peripheral ENO1-specific T cells mirror the intratumoral immune response and their presence is a potential prognostic f… DOI 10.3892/ijo.2016.3524↗
- Mario Milco D’Elios · 4 shared papers, 2013–2016 · strength 0.18
- Paper What is recent in pancreatic cancer immunotherapy? DOI 10.1155/2013/492372↗
- Paper Peripheral ENO1-specific T cells mirror the intratumoral immune response and their presence is a potential prognostic f… DOI 10.3892/ijo.2016.3524↗
- Paper Intra-tumoral IFN-γ-producing Th22 cells correlate with TNM staging and the worst outcomes in pancreatic cancer. DOI 10.1042/cs20150437↗
- Lapo Bencini · 3 shared papers, 2013–2016 · strength 0.13
- Paper Peripheral ENO1-specific T cells mirror the intratumoral immune response and their presence is a potential prognostic f… DOI 10.3892/ijo.2016.3524↗
- Paper Intra-tumoral IFN-γ-producing Th22 cells correlate with TNM staging and the worst outcomes in pancreatic cancer. DOI 10.1042/cs20150437↗
- Paper Ex vivo analysis of pancreatic cancer-infiltrating T lymphocytes reveals that ENO-specific Tregs accumulate in tumor ti… DOI 10.1007/s00262-013-1429-3↗
- Francesco Novelli · 3 shared papers, 2013–2016 · strength 0.13
- Paper Peripheral ENO1-specific T cells mirror the intratumoral immune response and their presence is a potential prognostic f… DOI 10.3892/ijo.2016.3524↗
- Paper Intra-tumoral IFN-γ-producing Th22 cells correlate with TNM staging and the worst outcomes in pancreatic cancer. DOI 10.1042/cs20150437↗
- Paper Ex vivo analysis of pancreatic cancer-infiltrating T lymphocytes reveals that ENO-specific Tregs accumulate in tumor ti… DOI 10.1007/s00262-013-1429-3↗
- Paola Cappello · 2 shared papers, 2013–2016 · strength 0.08
- Paper Peripheral ENO1-specific T cells mirror the intratumoral immune response and their presence is a potential prognostic f… DOI 10.3892/ijo.2016.3524↗
- Paper Ex vivo analysis of pancreatic cancer-infiltrating T lymphocytes reveals that ENO-specific Tregs accumulate in tumor ti… DOI 10.1007/s00262-013-1429-3↗
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.